BACE1 and Alzheimer disease: A recent study by Chatila et al. (2018) suggested that partial, rather than full inhibition of BACE1, may be a better therapeutic strategy for AD since complete loss of BACE1 activity has devastating effects on adult hippocampal neurogenesis [8].